AXSM · Axsome Therapeutics, Inc.
$213.67
-0.01 (0.00%)
At close · Aug 14
Market Cap
$11.19B
Shares
52.38M
Axsome Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Axsome Therapeutics, Inc. (AXSM) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$16.85M
−$44.82M
'22 Q3
22-11-07
·
$94.58M
−$11.22M
'23 Q1
23-05-08
▲429.5%
$46.70M
−$67.17M
'23 Q2
23-08-07
▲243.1%
$57.79M
−$62.20M
'23 Q3
23-11-06
·
$71.53M
−$98.65M
'23 Q4
24-02-20
▼20.7%
$75.00M
−$68.36M
'24 Q1
24-05-06
▲86.7%
$87.17M
−$79.34M
'24 Q2
24-08-05
▲81.3%
$104.76M
−$64.60M
'24 Q3
24-11-12
▲66%
$118.77M
−$74.91M
'24 Q4
25-02-18
▲62%
$121.46M
−$59.41M
'25 Q1
25-05-05
▲72.1%
$150.04M
−$47.97M
'25 Q2
25-08-04
▲63.2%
$170.99M
−$47.23M
'25 Q3
25-11-03
▲65%
$196.00M
−$28.56M
'25 Q4
26-02-23
▲57.4%
$191.20M
−$64.54M
'26 Q1
26-05-04
LATEST
▲45.5%
$218.38M
−$51.31M
'26 Q2
26-08-10
Earnings call
FY26 · Q2
2026-08-10
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
Confident tone
Alzheimer's disease agitation launch
Sales force expansion
Gross-to-net and financials
Revenue
$218.38M
▲ 45.5% YoY Diluted EPS
$-0.99
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
William Blair 46th Annual Growth Stock Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-04
Axsome Therapeutics, Inc. Q1 FY2026 Earnings Call
Confident tone
Pipeline advancement and NDA submissions
Avelity FDA approval in Alzheimer's disease agitation (ADA)
Sunosi and Symbravo commercial performance
Revenue
$191.20M
▲ 57.4% YoY Diluted EPS
$-1.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-23
Axsome Therapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone
Auvelity commercial growth
Cymbravo launch
Solriamfetol label expansion pipeline
Revenue
$196.00M*
▲ 65% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Axsome Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone
AXS-12 narcolepsy NDA
AUVELITY commercial performance
AXS-05 Alzheimer's disease agitation
Revenue
$170.99M
▲ 63.2% YoY Diluted EPS
$-0.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Axsome Therapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone
Commercial growth / Auvelity and Sunosi
SYMBRAVO launch
Solriamfetol expansion indications
Revenue
$150.04M
▲ 72.1% YoY Diluted EPS
$-0.97
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Axsome Therapeutics, Inc. Q1 FY2025 Earnings Call
Confident tone
Revenue growth & commercial performance
Solriamfetol lifecycle expansion (ADHD, MDD, BED, SWD)
Symbravo launch & EMERGE data
Revenue
$121.46M
▲ 62% YoY Diluted EPS
$-1.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-18
Axsome Therapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone
Late-stage pipeline and NDAs
Auvelity commercial growth
Solriamfetol label expansion
Revenue
$118.77M*
▲ 66% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Axsome Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
Auvelity commercial momentum
Solriamfetol (AXS-12 / Sunosi) life-cycle expansion
AXS-05 Alzheimer's disease agitation Phase 3 readouts
Revenue
$104.76M
▲ 81.3% YoY Diluted EPS
$-1.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Axsome Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
Auvelity commercial momentum
Solriamfetol pipeline expansion
Sunosi performance
Revenue
$87.17M
▲ 86.7% YoY Diluted EPS
$-1.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Axsome Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
Alzheimer's disease agitation program
Auvelity commercial performance
Solriamfetol pipeline expansion
Revenue
$75.00M
▼ 20.7% YoY Diluted EPS
$-1.44
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-20
Axsome Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone
Sunosi revenue and out-licensing
AXS-05 in Alzheimer's disease agitation (ADVANCE-2)
AXS-12 in narcolepsy (SYMPHONY trial)
Revenue
$71.53M*
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Axsome Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$57.79M
▲ 243.1% YoY Diluted EPS
$-1.32
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Axsome Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$46.70M
▲ 429.5% YoY Diluted EPS
$-1.54
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Axsome Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$94.58M
Diluted EPS
$-0.26
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Axsome Therapeutics, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Axsome Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$16.85M
Diluted EPS
$-1.07
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-23
Axsome Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$8.82M
Diluted EPS
$-1.06
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-02
Axsome Therapeutics, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-1.06
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Axsome Therapeutics, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Axsome Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$
Diluted EPS
$-0.93
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Axsome Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$
Diluted EPS
$-0.86
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Axsome Therapeutics, Inc. Q1 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Axsome Therapeutics, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Axsome Therapeutics, Inc. Q3 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Axsome Therapeutics, Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-08
Axsome Therapeutics, Inc. Q1 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Axsome Therapeutics, Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–30 of 30 earnings calls
Key facts
CIK
1579428
CUSIP
05464T104
13F (30d)
475 filings
468 filers
Visit website
Investor relations